Role of CD44 variant exon 6 in invasion of head and neck squamous cell carcinoma

Archives of Otolaryngology - Head and Neck Surgery

Volumn 126, Issue 10, 2000, Pages 1217-1223

  Kanke, Minoru ^a   Fujii, Masato ^a   Kameyama, Kaori ^a   Kanzaki, Jin ^a   Tokumaru, Yutaha ^a   Imanishi, Yorihisa ^a   Tomita, Toshihi ^a   Matsumura, Yasuhiro ^b  

^a KEIO UNIVERSITY   (Japan)

^b NATIONAL CANCER CENTER HOSPITAL   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

2F10; CD44V ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 2F10; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER INVASION; CANCER TISSUE; CELL INVASION; CELL MIGRATION; CELL PROLIFERATION; CONTROLLED STUDY; DOWN REGULATION; EXON; FEMALE; HEAD AND NECK CARCINOMA; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; METASTASIS; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA;

EID: 0033772064     PISSN: 08864470     EISSN: None     Source Type: Journal    
DOI: 10.1001/archotol.126.10.1217     Document Type: Article

References (13)

1. Jalkanen S, Bargatze RF, de los Toyos J, Butcher EC. Lymphocyte recognition of high endothelium: antibodies to distinct epitopes of an 85-95-kD glycoprotein antigen differentially inhibit lymphocyte binding to lymph node, mucosal, or synovial endothelial cells. J Cell Biol. 1987;105:983-990.
2. Arch R, Wirth K, Hofmann M, et al. Participation in normal immune responses of a metastasis-inducing splice variant of CD44. Science. 1992;257:682-685.
3. Günthert U, Hofmann M, Rudy W, et al. A new variant glycoprotein CD44 confers metastatic potential to rat carcinoma cells. Cell. 1991;65:13-24.
4. Matsumura Y, Hanbury D, Smith J, Tarin D. Non-invasive detection of malignancy by identification of unusual CD44gene activity in exfoliated cancer cells. BMJ. 1994;308:619-624.
5. Matsumura Y, Sugiyama M, Matsumura S, Hayle AJ, Robinson P, Smith JC, Tarin D. Unusual retention of introns in CD44 gene transcripts in bladder cancer provides new diagnostic and clinical oncological opportunities. J Pathol. 1995;177:11-20.
6. Seiter S, Arch R, Reber S, et al. Prevention of tumor metastasis formation by anti-variant CD44. J Exp Med. 1993;177:443-455.
7. Takahashi K, Eto H, Tanabe KK. Involvement of CD44 in matrix metalloproteinase-2 regulation in human melanoma cells. Int J Cancer. 1999;80:387-395.
8. Yamamichi K, Uehara Y, Kitamura N, Nakane Y, Hioki K. Increased expression of CD44v6 mRNA significantly correlates with distant metastasis and poor prognosis in gastric cancer. Int J Cancer. 1998;79:256-262.
9. Mulder JW, Kruyt PM, Sewnath M, et al. Colorectal cancer prognosis and expression of exon-v6-containing CD44 proteins. Lancet. 1994;344:1470-1472.
10. Kaufmann M, Heider KH, Sinn HP, von Minckwitz G, Ponta H, Herrlich P. CD44 variant exon epitopes in primary breast cancer and length of survival. Lancet. 1995;345:615-619.
11. Stauder R, Eisterer W, Thaler J, Günthert U. CD44 variant isoforms in nonHodgkin's lymphoma: a new independent prognostic factor. Blood. 1995;85: 2885-2899.
12. Favrot MC, Combaret V, Lasset C. CD44: a new prognostic marker for neuroblastoma. N Engl J Med. 1993;329:1965.
13. Spafford MF, Koeppe J, Pan Z, Archer PG, Meyers AD, Franklin WA. Correlation of tumor markers p53, bcl-2, CD34, CD44H, CD44v6, and Ki-67 with survival and metastasis in laryngeal squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 1996;122:627-632.